A5032193828- Acute Lymphoblastic Leukemia research
- Neuroblastoma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Glioma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Sarcoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Acute Myeloid Leukemia Research
- Diabetes Treatment and Management
- Receptor Mechanisms and Signaling
- Lymphoma Diagnosis and Treatment
- Ocular Oncology and Treatments
- Hematological disorders and diagnostics
- Brain Metastases and Treatment
- Pancreatic function and diabetes
- Antifungal resistance and susceptibility
- Bone and Joint Diseases
- Vascular Tumors and Angiosarcomas
- Ophthalmology and Eye Disorders
- Renal and related cancers
- Fungal Infections and Studies
- Corneal Surgery and Treatments
- Blood disorders and treatments
- Immune Cell Function and Interaction
- Chromatin Remodeling and Cancer
Sanofi (Germany)
2023-2024
Medical University of Graz
2013-2023
Zentrum für Kinderheilkunde
2001-2017
Universitätsklinik für Kinder und Jugendpsychiatrie
2017
Heinrich Heine University Düsseldorf
2008-2016
Graz University Hospital
1988-2015
Universitätskinderklinik
1996-2011
University of Graz
1995-2010
University of Duisburg-Essen
2010
University of Bonn
2006-2008
Adult stem cells, including adipose tissue-derived mesenchymal cells (MSCs) or ectomesenchymal dental follicle (DFCs), attract considerable attention for their potential to differentiate into lineages, which are of major interest in the field Regenerative Medicine. Purinergic receptors exert a wide range biological actions many cell and tissue types through extracellular nucleotides. Little is known about P2 adult changes expression levels during differentiation. All have been investigated,...
A series of 4-phenethynyldihydrocinnamic acid agonists the free fatty receptor 1 (FFA1) has been discovered and explored. The preferred compound 20 (TUG-424, EC50 = 32 nM) significantly increased glucose-stimulated insulin secretion at 100 nM may serve to explore role FFA1 in metabolic diseases such as diabetes or obesity.
Highlights•Haploidentical stem cell transplantation is a feasible and safe treatment option that can induce long-term remission in some patients.•A melphalan-based conditioning regimen yields the opportunity to transplant cells with low rates of TRM, toxicity, GVHD even highly pretreated patients.AbstractPediatric patients refractory or relapsed metastatic neuroblastoma (NBL) have poor prognosis despite autologous (SCT). Allogeneic SCT from haploidentical donor has remarkable alloreactive...
Abstract BACKGROUND To evaluate the feasibility and efficacy of intensive chemotherapy given prior to irradiation in pediatric patients with malignant glioma, Society Pediatric Oncology Germany started a randomized trial 1991. The high‐grade glioma strata had be closed because insufficient patient accrual. follow‐up data from these are reported. METHODS Fifty‐two World Health Organization (WHO) Grade 4 ( n = 27 patients) or WHO 3 anaplastic astrocytoma 25 between ages years 17 were available...
To assess the outcome of young children with supratentorial primitive neuroectodermal tumor (stPNET) treated by intensive postoperative chemotherapy alone compared treatment and delayed radiotherapy (RT).From 1987 to 1992, younger than 3 years age stPNET were enrolled in HIT-SKK87 trial Germany Austria. After surgery, low-risk patients received maintenance before RT. In high-risk patients, induction was followed until RT initiated. following trial, HIT-SKK92 methotrexate-based applied....
Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes. We here report discovery highly potent FFA1 agonist with favorable physicochemical pharmacokinetic properties. The compound efficiently normalizes glucose tolerance in diet-induced obese mice, an effect that is fully sustained after 29 days chronic dosing.
The free fatty acid receptor 1 (FFA1, also known as GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and is recognized an interesting new target for treatment of type 2 diabetes. Several series selective FFA1 agonists are already known. Most these derived acids (FFAs) or glitazones relatively lipophilic. Aiming the development potent, selective, less lipophilic agonists, terminal phenyl a compound was replaced by nitrogen containing heterocycles. This resulted in...
Summary Relapsed acute lymphoblastic leukaemia (ALL) is the most common cause for a fatal outcome in paediatric oncology. Although initial ALL cure rates have improved up to 80%, prognosis of recurrent remains dismal with event‐free‐survival (EFS) about 35%. In order analyse population‐based cohort uniform treatment disease, we examined children suffering from relapsed Austria past 20 years and validity currently used prognostic factors (e.g. time site relapse, immunophenotype). Furthermore,...
The free fatty acid 1 receptor (FFA1 or GPR40), which is highly expressed on pancreatic β-cells and amplifies glucose-stimulated insulin secretion, has emerged as an attractive target for the treatment of type 2 diabetes. Several FFA1 agonists containing para-substituted dihydrocinnamic moiety are known. We here present a structure-activity relationship study this compound family suggesting that central methyleneoxy linker preferable smaller compounds, whereas methyleneamine gives higher...
Trifluperidol (2a) is a dopamine (D2) receptor antagonist of the butyrophenone type. Carbon/silicon exchange (sila-substitution) in 4-position piperidine ring 2a (R3COH → R3SiOH) results sila-trifluperidol (2b). The silanol 2b was synthesized multistep synthesis, starting from triethoxy(vinyl)silane, and isolated as hydrochloride 2b·HCl. Compound 2b·HCl structurally characterized by single-crystal X-ray diffraction solution NMR spectroscopy, stability aqueous solutions at different pH values...
Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity. Here, we report the favourable outcome in 81 paediatric APL patients treated according to consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen combination all-trans-retinoid acid (ATRA). Outcomes achieved by a reduced anthracycline dose (350 mg/m(2)) were comparable...
FFA1 (GPR40) is a new target for treatment of type 2 diabetes. We recently identified the potent agonist TUG-469 (5). Inspired by structurally related TAK-875, we explored effects mesylpropoxy appendage on 5. The significantly lowers lipophilicity and improves metabolic stability while preserving potency, resulting in discovery 13.
The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging a new target for the treatment type 2 diabetes. Several FFA1 agonists are known, but majority these suffer from high lipophilicity. We have previously reported agonist 3 (TUG-424). here describe continued structure-activity exploration optimization this compound series, leading to discovery more potent 40, with low lipophilicity, excellent in vitro metabolic...
Background Children and adolescents with Non-Hodgkin lymphoma (NHL) mature B-cell leukemia (B-ALL) have an excellent prognosis contemporary chemotherapy stratified according to the histologic subtype clinical stage of disease. However, a small subset patients does not respond front-line therapy or suffers from early relapse. Procedure A retrospective analysis was performed assess incidence, treatment, outcome all children relapsed progressed NHL B-ALL diagnosed in Austria between 1986 2003...
We analyzed outcome of a population-based cohort 74 children with second and third acute lymphoblastic leukemia (ALL) relapse aimed to identify prognostic factors. Duration previous remission site appeared relevance as patients duration >1.5 years isolated extramedullary did better. Neither patient bone marrow who underwent allogeneic transplantation nor T-cell ALL survived. Overall, 7 (9%) are in long-term remission. Stem cell seemed be the only curative option for systemic B-cell precursor...